001041313 001__ 1041313
001041313 005__ 20250414120458.0
001041313 0247_ $$2doi$$a10.1007/s00259-024-07038-5
001041313 0247_ $$2ISSN$$a1619-7070
001041313 0247_ $$2ISSN$$a1619-7089
001041313 0247_ $$2datacite_doi$$a10.34734/FZJ-2025-02212
001041313 0247_ $$2pmid$$a39762634
001041313 0247_ $$2WOS$$aWOS:001390889200001
001041313 037__ $$aFZJ-2025-02212
001041313 082__ $$a610
001041313 1001_ $$0P:(DE-Juel1)171957$$aVerger, Antoine$$b0$$eCorresponding author
001041313 245__ $$aJoint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0
001041313 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2025
001041313 3367_ $$2DRIVER$$aarticle
001041313 3367_ $$2DataCite$$aOutput Types/Journal article
001041313 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1744283111_2926
001041313 3367_ $$2BibTeX$$aARTICLE
001041313 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001041313 3367_ $$00$$2EndNote$$aJournal Article
001041313 520__ $$aThis joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [18F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with brain metastases. This practice guideline will define procedure standards for the application of PET imaging in patients with brain metastases in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers.Keywords: Brain metastases; Brain metastasis; FDG; FDOPA; FET; Fluciclovine; Metastatic brain tumors; Methionine; PET; Recurrence.
001041313 536__ $$0G:(DE-HGF)POF4-5252$$a5252 - Brain Dysfunction and Plasticity (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001041313 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001041313 7001_ $$00000-0002-8005-2833$$aTolboom, Nelleke$$b1
001041313 7001_ $$00000-0003-4664-1965$$aCicone, Francesco$$b2
001041313 7001_ $$0P:(DE-HGF)0$$aChang, Susan M.$$b3
001041313 7001_ $$0P:(DE-HGF)0$$aFurtner, Julia$$b4
001041313 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b5$$ufzj
001041313 7001_ $$0P:(DE-HGF)0$$aGempt, Jens$$b6
001041313 7001_ $$0P:(DE-HGF)0$$aGuedj, Eric$$b7
001041313 7001_ $$0P:(DE-HGF)0$$aHuang, Raymond Y.$$b8
001041313 7001_ $$0P:(DE-HGF)0$$aJohnson, Derek R.$$b9
001041313 7001_ $$0P:(DE-HGF)0$$aLaw, Ian$$b10
001041313 7001_ $$0P:(DE-HGF)0$$aLe Rhun, Emilie$$b11
001041313 7001_ $$0P:(DE-HGF)0$$aShort, Susan C.$$b12
001041313 7001_ $$0P:(DE-HGF)0$$aBent, M. J. Van den$$b13
001041313 7001_ $$0P:(DE-HGF)0$$aWeehaeghe, Donatienne Van$$b14
001041313 7001_ $$0P:(DE-HGF)0$$aVogelbaum, Michael A.$$b15
001041313 7001_ $$0P:(DE-HGF)0$$aWen, Patrick Y.$$b16
001041313 7001_ $$00000-0003-0953-7624$$aAlbert, Nathalie L.$$b17
001041313 7001_ $$00000-0003-3541-2315$$aPreusser, Matthias$$b18
001041313 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-024-07038-5$$gVol. 52, no. 5, p. 1822 - 1839$$n5$$p1822 - 1839$$tEuropean journal of nuclear medicine and molecular imaging$$v52$$x1619-7070$$y2025
001041313 8564_ $$uhttps://juser.fz-juelich.de/record/1041313/files/PDF.pdf$$yOpenAccess
001041313 909CO $$ooai:juser.fz-juelich.de:1041313$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001041313 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)171957$$aForschungszentrum Jülich$$b0$$kFZJ
001041313 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b5$$kFZJ
001041313 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5252$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001041313 9141_ $$y2025
001041313 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
001041313 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
001041313 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
001041313 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001041313 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-05
001041313 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
001041313 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
001041313 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
001041313 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
001041313 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001041313 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-05
001041313 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
001041313 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
001041313 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
001041313 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
001041313 920__ $$lyes
001041313 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001041313 980__ $$ajournal
001041313 980__ $$aVDB
001041313 980__ $$aUNRESTRICTED
001041313 980__ $$aI:(DE-Juel1)INM-3-20090406
001041313 9801_ $$aFullTexts